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Chromatin is the essential medium connecting regulatory signals such as transcription factors and 
signaling pathways to the alteration of gene activity and cellular phenotypes. Aberrant chromatin 
(epigenetic) environment plays an important role in carcinogenesis.  
 
The fundamental unit of chromatin is the nucleosome which is composed of a histone core 
wrapped with 145-147 base pairs of DNA around. In the last decades, great efforts have been made to 
delineate the role of aberrant DNA methylation and chromatin/histone-remodeling factors in 
oncogenesis. However, recent evidence has merged that the dysregulation of histone chaperones also 
acts as a cancer-driver. Anti-silencing function 1 (ASF1) is the most conserved histone H3-H4 
chaperone, regulating histone metabolism. ASF1 proteins include two paralogs ASF1A and ASF1B in 
mammals. ASF1A and ASF1B have been reported as oncogenes in human cancers. Data from the 
Cancer Genome Atlas (TCGA) and the Genotype-Tissue Expression (GTEx) databases show that 
ASF1A and ASF1B are overexpressed in 20 and 24 different types of cancers, respectively. Thus, in 
this thesis, I explored the oncogenic role of histone chaperone ASF1 and underlying molecular 
mechanisms in several solid tumors.  
 
In Paper I, the role for ASF1A in gastrointestinal cancer (GIC) was investigated. We discovered 
that ASF1A interacted with the oncogenic transcription factor β-catenin and promoted the 
transcription of β-catenin target genes (c-MYC, cyclin D1, ZEB1 and LGR5). The increased 
expression of these genes stimulated proliferation, stemness and migration/invasion of GIC cells. 
Over-expression and knockdown of ASF1A boosts and inhibits in vivo tumor growth and/or 
metastasis in mouse models, respectively. Higher levels of ASF1A expression predict significantly 
shorter patient survival in colorectal cancer (CRC). Further analyses of the Gene Expression Omnibus 
dataset validate higher ASF1A expression predicting a poor prognosis in CRC patients. Taken 
together, this study reveals the novel function of ASF1A as a transcription co-factor independent of its 
canonical role and the potential value of ASF1A for outcome prediction and targeted treatment in 
GIC. 
 
In Paper II, we show that ASF1A overexpression is widespread in human malignancies and is 
required for the infinite proliferation of cancer cells. When ASF1A was knocked-down in wild-type 
(wt) p53 carrying cells derived from hepatocellular carcinoma (HCC) and prostate cancer (PCa), DNA 
damage response was activated and up-regulation of p53-p21cip1 expression consequently occurred. 
These cells eventually underwent cellular senescence. Higher ASF1A expression and/or lower p21cip1 
expression predicts a poor outcome in HCC patients. Thus, ASF1A may be a therapeutic target and a 
prognostic factor in HCC and other cancers. 
 
In Paper III, we evaluated whether ASF1B has diagnostic and prognostic values in 
adrenocortical carcinoma (ACC) and regulates invasion and metastasis. We first analyzed TCGA and 
GTEx data and found that the ASF1B gene was amplified in two thirds of ACC tumors and associated 
with its overexpression. ASF1B expression correlates with the ACC diagnostic criteria of the Weiss 
scoring system. Higher ASF1B expression and ASF1B copy number predict a poor outcome in the 
TCGA cohort of ACC patients. Knockdown of ASF1B in ACC cells impairs migration and invasion 
ability by inhibiting expression of the transcription factor FOXM1; whereas ASF1B over-expression 
exhibits opposing effects. These findings suggest that ASF1B may be a useful factor for ACC 
diagnostics and prognostication, and potentially a novel target for ACC therapy as well.  
 
Collectively, the results presented in this thesis gain profound insights into the oncogenic role of 
ASF1 in several solid tumors and demonstrated novel activities of ASF1 proteins beyond their 
conserved histone chaperone function. These findings will inspire further exploration of both the 
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1.1 CELL FATE AND CANCER 
It is always fascinating to think about how one fertilized egg develops to an organism 
composed of hundreds of different types of cells, all of which share one genome but express 
different sets of genes at different levels. Each cell identifies itself and restricts its role under 
the architecture of the whole life system, though in some pathological cases, cells lose their 






1.1.1 Establishment and maintenance of cellular identity 
Cells distinguish themselves from other cell types by expressing a unique spectrum of genes 
and generating a specific phenotype[1, 2]. This gene expression pattern and the phenotype 
must undergo two processes --- establishment and maintenance[1]. The establishment of 
cellular identity depends largely on how the pluripotential original cell coordinates hundreds 
of transcription factors to bind to specific DNA motifs to activate or repress the expression of 
cell lineage genes[3]. Genotype plays an important role in the establishment period and 
somehow decides the phenotype. In the maintenance period, a lot more non-DNA sequence 
specific chromatin cofactors are involved in to create and maintain certain chromatin states 
Figure 1. Cell identification in development and cancer. Life starts from a zygote with one genome. 
Stage- and cell type-specific transcription factors (TFs) initiate cell differentiation. Epigenomic factors may 
further influence the differentiation paths of the precursor cells. Under some disease conditions such as 
cancer, the differentiated cells may acquire oncogene mutations and undergo aberrant epigenetic re-
programming and thus rewrite their fate. 
 
2 
through cell division --- delivering the precise hereditary information from the parental cells 
to the offspring cells, sometimes without the participation of the initial transcription 
factors[4]. Epigenetic regulation is inevitable to be mentioned in the maintenance phase --- 
passing down the alternative chromatin states without changing the DNA sequence. 
1.1.2 Erasion of the barriers 
Normally, cell fate is strictly and precisely restricted through the whole life cycle. A series of 
barriers are set up to limit the function and longevity of each cell type. However, once a 
neoplastic program happens to be switched on, the abnormal cells explore every means to 
break through these barriers and ultimately become malignant and immortalized. It is usually 
a long-time and multi-step process for the malignant transformation. The famous and classic 
theory that Hanahan and Weinberg brought up in 2000 and 2011 highlights eight hallmarks of 
cancer, which in turn are also the typical barriers protecting cell fate from tumorigenesis[5, 
6]. Understanding the underlying molecular mechanisms of how cells overcome the obstacles 
and manipulate their destiny will be very crucial for the corresponding therapeutic 
intervention. 
1.1.3 Genetic and epigenetic interplay 
DNA sequence is undoubtedly an important determinant of cell fate. However, because 
eukaryotic genomic DNA is packaged into a highly ordered chromatin structure, how to 
approach and translate the DNA information correctly becomes another obstacle for 
eukaryotic cells on the road of self-identification[7]. Therefore, apart from the important 
information written in DNA, cellular identity is established and maintained with the aid of 
chromatin environment. The concept of epigenetics was then raised referring to “the study of 
molecules and mechanisms that perpetuate alternative gene activity states in the context of 
the same DNA sequence”[1].  
Most human cancers display both genetic and epigenetic defects which inextricably interplay 
with each other[8-10]. Genetic factors such as sequence polymorphisms and mutations can 
affect epigenomic landscapes by altering chromatin accessibility or tempering histone and 
DNA modifying enzymes, chromatin remodelers and other chromatin factors[1]. For 
instance, pediatric tumors usually have a high possibility of harboring mutations in genes 
encoding chromatin modifying enzymes and have abnormality in DNA methylation[11, 12]. 
These types of mutations are also observed in adult tumors and are found to have a great 
influence on the epigenome[13]. For example, mutations in the genes IDH1 and IDH2 in 
gliomas and acute myeloid leukemia drive the pathological phenotype by inhibiting DNA 
demethylases and histone demethylases[14-16]. Epigenetic factors also influence the genome. 
For instance, chromatin states heavily affect the binding efficiency of transcription factors 
with DNA elements and thus regulate gene expression[17]. Epigenetic factors are also the 
intermediate between the environment and the intrinsic genome and can deliver 




1.1.4 Theories on cell fate determination and how the rebellious cells 
develop to cancer 
There is a metaphor called ‘epigenetic landscape’ proposed by the British developmental 
biologist Conrad H. Waddington[18]. The landscape is composed of a series of ridges and 
valleys and a ball is on the highest top where is its starting point to go down. This metaphor 
can be used to explain cell fate determination. The ball on the top is a progenitor cell. The end 
of each valley represents the final destiny the progenitor cell might drop to and the valleys 





People have created multiple theories and models from the ‘Epigenetic landscape’, two of 
which are interesting. The first theory assumes that the organic system is an attractor 
network[19, 20]. It proposes that there are ‘attractors’ (potential well) among cell cohorts to 
restrict them in their destiny. The attractor is generated by the gene regulatory network 
(GRN) in the high-dimensional gene expression state space and can facilitate the cell to 
withstand the stochastic molecular fluctuations. The destabilization of their high-dimensional 
attractor state can cause the transition of cell fate. The ‘battle’ between an old attractor and a 
new one might be the cause the destabilization. There are relevant observations showing that 
the normal tissue microenvironment can shift the balance of the signal network to the 
precancerous state and rewrite the tumor fate in breast cancer, which creates a new angle for 
cancer treatment[21]. Oppositely, a tumor microenvironment can accelerate the 
tumorigenesis process and manipulate the normal cells to become malignant[6, 22]. 
The second theory assumes that the chromatin can adjust the heights of the ridges between 
the canals in the proposed epigenetic landscape by restricting the expression of lineage-
specific genes. An overly permissive chromatin state can be created by either genetic or 
environmental factors. This state can result in epigenetic plasticity which makes the 
stochastic alteration of regulatory pathways possible and facilitates the selection of 
premalignant cells, and finally fuels the hallmarks of cancer[23]. Cancer hallmarks can be 
realized through the silencing of tumor suppressors, the activation of oncogenes by aberrant 
enhancers or cell fate transitions. From an epigenetic angle, epigenetic plasticity and 
Figure 2. The Epigenetic Landscape. From the book <The strategy of the genes> written by Conrad H. 
Waddington and first published in 1957. 
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aberrations undoubtedly contribute to these processes. For example, disruption of chromatin 
insulators promotes proliferation by activating PDGFRA gene[24]. Promoter 
hypermethylation or EZH2 hyperactivity causes silencing of tumor suppressor p16ink4a[25, 
26]. DNMT3A or IDH mutations induce cell death resistance by altering DNA damage 
response[27, 28]. Mutations in genes coding histone H3.3 or its chaperones can drive 
replicative immortality[29, 30].  
 
1.2 EPIGENETICS 
1.2.1 Definition  
Waddington first defined ‘epigenetics’ in 1942 as changes in phenotype without changes in 
genotype in the context of development[3, 31-33]. During the next three-quarters of a 
century, the understanding of this concept has evolved and now it is generally acceptable to 
refer to ‘epigenetics’ as the study of molecules and mechanisms that regulate gene activity 
state without involving changes in DNA sequence[1]. 
1.2.2 History of epigenetic research 
The history of epigenetic research can be split into two periods: the fundamental age which 
can be traced back to the 19th century and the modern era which is from 1996 till now[34]. In 
the years between 1869 and 1928, the work completed by Miescher, Flemming, Kossel and 
Heitz included discovery of nucleic acids, chromatin and histone proteins, which was a 
foundation for the cytological distinction between euchromatin and heterochromatin[35]. In 
the following century, many epigenetic molecules and modifications were recognized or 
detected, including DNA methylation in the mid-1970s, the nucleosome (the chromatin 
subunit model) in 1974 and histone modifications in mid-1960s[36-38]. From the year 1996, 
along with the discovery of multiple histone and DNA modification enzymes and the boost of 
novel technologies such as genome-wide chromatin profiling, epigenetic research has entered 
a modern era[39]. More histone modifications and histone variants were recognized and the 
hypothesis of a histone code was raised[40-42]. Nucleosome remodeling and non-coding 
RNA were also brought into people’s eyesight[34]. 
1.2.3 Major epigenetic information carriers 
1.2.3.1 Histone modifications 
Histone modifications are covalent post-translational modifications (PTMs) on histone 
proteins. There are a variety of forms of histone modifications including methylation, 
acetylation, phosphorylation, ubiquitylation, sumoylation, etc.[34]. Different histone 
modifications convey different kinds of information. For example, histone lysine H3K9me3 
is a repressive signal, while histone H3K4 methylation is associated with active 
promoters[34]. Histone modification information is edited by ‘writers’ and ‘erasers’ and 
accessed by ‘readers’[40, 43]. The ‘writers’ and ‘erasers’ are generally enzymes which can 
add or remove post-translational modifications to or from histone proteins. Histone 
acetyltransferases (HATs) and histone lysine methyltransferases (KMTs) are typical histone 
‘writers’. The ‘erasers’ include for example histone deacetylase (HDAC) family enzymes and 
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histone demethylases. The histone modification ‘readers’ are molecules which can offer an 
accessible surface to interact with a modified histone residue and determine the modification 
and state specificity[44]. The ‘readers’ can also distinguish the flanking amino acids to 
achieve sequence specificity. There are a wide range of histone modification readers. For 
instance, the bromo domains and the tandem PHD domain can recognize acetylated lysines 
(AcKs)[45, 46]. The PHD, chromo, WD40, Tudor, double/tandem Tudor, MBT, Ankyrin 
Repeats, zf-CW and PWWP domains can recognize lysine methylation (MeK) 
modifications[44]. 
1.2.3.2 Canonical histones and histone variants  
Chromatin is the physiological form of the eukaryotic genome and is composed of DNA and 
histone proteins. The canonical histone proteins include H1, H2A, H2B, H3, H4 and H5. In 
some contexts, the canonical histone proteins can be exchanged by histone variants. Histone 
variants have different sequences or structures from the canonical histones and compose a 
small portion of histone pool[47]. Usually they are tissue specific and are more prevalent in 
H2A, H3 and linker histone H1 family[48, 49]. For example, H2A variants consist of H2A.Z, 
H2A.X and macroH2A (mH2A). H3 variants include CENP-A and H3.3[47]. Histone 
variants play important roles in regulating chromatin segregation and gene expression. Some 
recently accumulated evidences have shown the role of histone variants in cancer 
progression. For instance, H2A.Z is an oncogenic histone variant and has increased 
expression in colorectal, breast, lung and bladder cancers[47, 50, 51]. H2A.X is involved in 
head and neck squamous cell carcinoma, non-Hodgkin lymphoma, gastrointestinal stromal 
tumor and breast cancer[52-55]. The histone variant mH2A suppresses melanoma 
progression by regulating CDK8[56].  
1.2.3.3 DNA methylation 
DNA methylation usually refers to the covalent addition of a methyl group on the 5th carbon 
of cytosine by DNA methyltransferases (DNMTs)[57]. DNA methylation has been well 
studied in the epigenetic regulation of gene expression, especially for 5-methylcytosine 
(5mC)[36]. The association between DNA methylation and gene expression was well 
established by 1980, where what was called CpG islands was discovered[58, 59]. CpG 
islands are prevalent present in human genome, especially at the transcription and promoter 
region[60]. In normal tissues, most of CpG islands have a low methylation level or are 
unmethylated, while are often found aberrantly methylated in tumor cells[57, 61].  
1.2.3.4 Non-coding RNA 
A non-coding RNA (ncRNA) usually refers to a functional RNA molecule which is not 
translated into a protein. There are several classes of ncRNAs including transfer RNAs 
(tRNAs) and ribosomal RNAs (rRNAs), and small RNAs such like microRNAs, siRNAs, 
piRNAs, snoRNAs, snRNAs, exRNAs, scaRNAs and the long ncRNAs (lncRNAs). Some 
ncRNAs are involved in post-translational regulation such as microRNAs, and some others 
are relevant to transcriptional regulation. The most representative example of non-coding 
RNA mediated regulation may be the X-chromosome inactivation[62]. Some nuclear 




1.2.4 Epigenetic inheritance versus plasticity 
Many epigenetic characteristics can be transmitted across cell divisions and also through 
generations after they are established even when the original signals are absent[1]. Examples 
include heterochromatin inheritance in yeast, genomic imprinting in mammals and 
vernalization in plants[1]. It is much more difficult to achieve epigenetic inheritance than 
genomic inheritance because nucleosomes lack a DNA-template based duplication system. 
The inheritance of epigenetic marks has to depend on other mechanisms to survive DNA 
replication and mitosis. A series of chromatin factors such as heterochromatin complex, 
Polycomb complex, Trithorax complex, DNMT1-UHRF1 and EZH2 are involved in this 
process[63-66]. Besides, the inheritance of single nucleosome mark seems to be challenging 
and usually the establishment of chromatin hereditary domains requires several or hundreds 
of kilobases in size[67-70]. In summary, from DNA methylation, nucleosome modifications 
to 3D chromatin structures such as topologically associating domains (TADs), epigenetic 
inheritance includes multiple layers[71-74]. The multiple epigenetic machineries interact and 
cooperate to stabilize heritable states. Each layer adds an extent of stability, while at the same 
time diversifies the plasticity due to the reversible character of epigenetic modifications[75]. 
DNA sequence is very important and acts as the fundamental basis in some tough cases for 
the epigenetic inheritance system by offering binding sites for transcription factors or RNA-
mediated mechanisms[76].  
1.2.5 Novel approaches in epigenetic research 
1.2.5.1 Chromatin accessibility and chromosome conformation measurement 
Chromatin accessibility is crucial for transcription factors or transcription machineries to 
reach DNA information[77]. Based on polymerase chain reaction (PCR) technology[78], a 
number of quantitative methods have been designed and developed to measure site-specific 
chromatin accessibility using endonucleases and ligation-mediated PCR[79, 80], including 
DNase I hypersensitive site sequencing (DNase-seq)[81, 82], Assay for transposase-
accessible chromatin using sequencing (ATAC-seq)[77, 83], micrococcal nuclease 
sequencing (MNase-seq)[84, 85] and Nucleosome occupancy and methylome sequencing 
(NOMe-seq)[77, 86]. The higher order of chromatin affects chromatin accessibility. A series 
of chromosome conformation capture (3C) based technologies have been developed to 
analyze the spatial organization of chromatin in cells, such as 3C, Chromosome conformation 
capture-on-chip (4C), Chromosome conformation capture carbon copy (5C), Hi-C, ChIP-loop 
and ChIA-PET[87-91]. 
1.2.5.2 Single-cell and lineage-tracing techniques 
The ability to trace molecular changes through time and cell division is important for 
epigenetic inheritance study. Multi-labeling by introducing barcodes has solved the problem 
of limited labeling in dividing cells. Single-cell technology based quantitative measurements 
have also been matured. The combination of advanced lineage-tracing techniques and single-
cell ‘omic’ technologies can help to better understand the gene expression timeline of 
different cell lineages[1, 92]. 
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1.2.5.3 Genome editing and super-resolution microscopy technologies 
The boost of genome editing methods such as CRISPR-Cas9 in the recent decade has made it 
possible and then convenient to edit the genome precisely[93]. This means that most of the 
epigenetic molecules and enzymes can be deleted or introduced in a more flexible way in 
multiple contexts for better functional study[94, 95]. Besides, the development of super-
resolution microscopy technologies also contributes to epigenetic research for example in 
combination of single-cell Hi-C technology in chromosome conformation study[96]. 
 
1.3 HISTONE CHAPERONE ASF1 
1.3.1 The nucleosome 
The nucleosome is the fundamental unit of the chromatin[97]. One nucleosome unit is 
composed of a histone core wrapped with 145-147 base pairs of DNA[98]. The histone core 
consists of a histone (H3-H4)2 tetramer and two histone H2A-H2B dimers[98]. Since DNA is 
compacted around nucleosomes, nucleosomes have to be disassembled before DNA 
replication, transcription and repair. After these processes, nucleosome components are 
assembled to form new nucleosomes[98]. 
1.3.2 Histone chaperones 
Histone chaperones are a diverse group of histone-binding proteins with distinct structural 
and functional properties. They help prevent or reverse incorrect interactions that occur when 
interactive surfaces are exposed to the environment before histones are assembled into 
chromatin[99, 100]. For instance, chromatin assembly factor 1 (CAF-1) is a H3.1-H4 
chaperone. Nucleosome assembly protein 1 (Nap1) is a H3-H4 and H2A-H2B chaperone[99]. 
Although histone chaperones are broadly involved in chromatin assembly, they are not a 
permanent component of the final product --- the nucleosome[99]. Besides, histone 
chaperones also participate in multiple processes of histone metabolism, such as histone 
storage, transport, PTM and histone recycle[100].  
Dysregulation of histone chaperones plays an important role in a variety of human diseases, 
especially in cancer[98, 101]. It was reported that mutations on histone chaperones ATRX 
and Daxx genes were detected in pancreatic neuroendocrine tumors[102]. Histone chaperone 
CHAF1A was observed to promote gastric cancer (GC) pathogenesis via upregulation of 
cMYC and CCND1 expression[103]. The histone chaperone FACT complex accelerates liver 
cancer progression by mediating oxidative stress response[104]. 
1.3.3 ASF1 --- a conserved H3-H4 histone chaperone 
Anti-silencing function 1 (ASF1) is the most conserved histone H3-H4 chaperone, regulating 
histone metabolism in many biological processes, such as replication, transcription and DNA 
repair[105]. Among its conserved functions, on the one hand, ASF1 interacts with histone 
H3-H4 dimer and forms a heterotrimeric complex with H3 and H4[106]. On the other hand, 
ASF1 binds to two other histone H3-H4 co-chaperones: CAF-1 and histone regulator A 
(HIRA)[107]. CAF-1 is composed of three subunits named p48, p60 and p150. CAF-1 is 
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crucial for replication and DNA repair-dependent histone deposition, whereas HIRA has a 
more significant role in DNA repair-independent histone deposition[108]. 
1.3.4 ASF1 in nucleosome assembly and disassembly 
1.3.4.1 ASF1 in replication-coupled nucleosome assembly 
During replication, the chromatin needs to be reassembled after DNA is replicated. In this 
process, both newly synthesized and parental histones are deposited to the newly replicated 
and parental DNA[99]. The initial step of chromatin assembly is to load histones H3/H4 onto 
the DNA. Then the two H2A/H2B dimers are deposited, finally followed by the incorporation 
of linker histone H1[99]. The de novo incorporation of newly synthesized histone H3/H4 
after replication is mediated by CAF-1[99]. CAF-1 binds to the replication-specific histone 
H3.1 instead of the replication-independent histone H3.3[109]. The task of ASF1 is to deliver 
the newly synthesized histone H3-H4 to CAF-1. Then ASF1 has to be removed from the 
interface with H3 because it is the same interface for H3 and H4 to form the H3/H4 
heterotetramer[99]. The replication-coupled nucleosome assembly progress is illustrated in 






1.3.4.2 ASF1 in replication-independent nucleosome assembly 
In the transcription process, nucleosomes also pose as barriers for the transcriptional 
machinery and thus need to go through disassembly and reassembly as well. HIRA and death 
domain-associated protein (Daxx) are mediators of replication-independent nucleosome 
assembly[98]. They facilitate histone H3.3-H4 deposition. The ASF1A-H3.3-H4 complex is 
transferred to HIRA at genic regions. Daxx assists deposition of H3.3-H4 at telomere 
Figure 3.  Replication-coupled nucleosome assembly. In replication-coupled nucleosome assembly, ASF1 
passes the H3-H4 dimer to downstream chaperones CAF-1 and Rtt106. In human cells, CAF-1 and Rtt106 
assemble (H3-H4)2 tetramers and deposit them to newly synthesized DNA. The interaction between CAF-1 
and proliferating cell nuclear antigen (PCNA) facilitates the deposition process. (Illustration graph is 
modified based on Burgess et al., Nat Struct Mol Biol, 2013. 20(1): p. 14-22.) 
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1.3.4.3 ASF1 in nucleosome disassembly 
Nucleosomes need to be disassembled before replication and transcription. It is reported that 
around 300bp naked DNA lies ahead of the replication fork while approximately 250bp is 
behind the replication fork[110, 111]. The H2A/H2B histones are removed first, followed by 
the more stable histone H3/H4. ASF1 facilitates the removal of H3/H4 from DNA. The 
histones in the ASF1-H3/H4-MCM complex have a similar posttranslational modification 
pattern as the parental chromatin, which suggests the role of ASF1 in nucleosome 
disassembly[112]. The nucleosome disassembly process is presented in Figure 5[99]. 
 
Figure 4. Replication-independent nucleosome assembly. In human cells, nucleosomes pose as barriers for 
the transcriptional machinery and thus undergoes disassembly and reassembly during transcription. This 
process is known as replication-independent nucleosome assembly. ASF1 delivers histone H3.3-H4 to 
downstream chaperone HIRA at genic regions, possibly through interactions with RNA polymerase II and 
DNA. In telomere regions, H3.3-H4 is deposited by Daxx. The mechanisms of Daxx-mediated histone 
deposition are still unclear. (Illustration graph is modified based on Burgess et al., Nat Struct Mol Biol, 









1.3.4.4 ASF1 in DNA repair 
There are several lines of evidence showing ASF1 participating in DNA repair. For example, 
ASF1A-facilitated histone H3K56 acetylation (H3K56ac) is necessary for nucleosome 
reassembly after DNA damage to promote DNA repair[113]. ASF1 assists checkpoint 
recovery after DNA damage repair[114]. ASF1A and ATM can also modulate UV-induced 
cell-cycle checkpoint recovery[115]. Moreover, ASF1A has a direct role in DNA double-
strand break repair[116]. We have observed that ASF1A deletion triggers DNA damage 
response by activating the p53 signaling pathway[105]. 
1.3.5 Evolution of the ASF1 gene 
ASF1 was first identified in yeast as a single protein[117]. On the road of evolution, the ASF1 
gene duplicated itself at the origin of jawed vertebrates[107]. Afterwards, ASF1 passed down 
in most vertebrates as two paralogs which were then named ASF1A and ASF1B in 
mammals[107]. After the duplication incident, ASF1A gene relocated into an intron of the 
minichromosome maintenance complex component 9 (MCM9) gene at the ancestor of 
tetrapods, leaving ASF1B gene at the original spot[107]. The new genomic environment at 
MCM9 provided ASF1A gene a different GC content and replication timing, which might fuel 
the two paralogs towards different evolutionary directions[107]. 
1.3.6 Functional divergence of ASF1A and ASF1B 
1.3.6.1 Structure-based interaction specificities 
ASF1 gene has three structural regions: core, N- and C-terminus. The main core region is 
highly conserved while the N- and C- terminal regions have varied. The conserved core 
binding domain provides basis for the interaction with histone H3-H4 and cochaperones. The 
N-terminus of ASF1A keeps almost all the characters of their ancestor, whereas the ASF1B 
N-terminus largely evolves away. It is reported that the divergence of ASF1B N-terminal 
residuals decreases the affinity for HIRA, which is in charge of replication-independent 
histone deposition together with ASF1[108]. Instead of interacting with HIRA, ASF1B has 
higher affinity for CAF-1 p60, which plays an important role in replication-dependent histone 
deposition. The C-terminus domain of ASF1 is a phosphorylation substrate in both human 
and mouse[118, 119]. The ASF1A C-terminus remained quite stable since the ancestor of 
amniotes while ASF1B C-terminus kept evolving at similar rates all the time[107]. The 
positive selection on ASF1A C-terminus at amniotes might be an indicator of acquisition of 
novel functions of this gene in this lineage[107]. In human and mouse, many sites on ASF1A 
C-terminus mutated to Ser and Thr residues, whereas ASF1B C-terminus lost some Ser 
Figure 5. Nucleosome disassembly and assembly at replication fork. The nucleosomes ahead of the 
replication fork need to be disassembled before the replication machinery arrives. MCM2-7 helicase 
complex is needed for unwinding the DNA duplex. PCNA keeps the processivity of DNA replication. In 
human cells, histone chaperone ASF1 is responsible for removing histone H3-H4 from double-strand DNA. 
ASF1 binds to the MCM complex through the parental histones H3 and H4. The parental histones in this 
complex provide the information that the histones bound to ASF1 have been removed from the DNA ahead. 
Similar mechanisms are observed in H2A/H2B chaperones such as histone chaperone FACT. (Illustration 
graph is modified based on Ransom et al., Cell, 2010. 140(2): p. 183-95.) 
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residues and gained many Gly ad Pro residues[107]. ASF1A presents more phosphorylation 
sites on the C-terminus due to the presence of multiple Ser and Thr residues. 
1.3.6.2 Biological function divergence of ASF1A and ASF1B 
Although ASF1A and ASF1B preserved most of the ancestral characters, they acquired some 
novel and distinct functions. ASF1A played an important role in histone H3K56 
acetylation[120, 121]. The interaction between ASF1A and histone H3-H4 is essential for 
histone H3K56 acetylation[121]. ASF1A is also involved in maintenance of pluripotency and 
cellular reprogramming[122]. ASF1B functions more in proliferation regulation. For 
example, ASF1B can promote human β-cell proliferation by recruiting histone H3.3[123].  
 
1.4 ASF1 IN CANCER 
Among numerous epigenetic factors, histone chaperones distinguish themselves in regulating 
all aspects of histone metabolism, which is the fundamental process of most chromatin-based 
epigenetic activities[122]. ASF1A and ASF1B have been reported as oncogenes in many 
types of cancer and predict a poor outcome in patients with higher expression, including 
gastrointestinal, liver, prostate and breast cancer[105, 124, 125]. Data from The Cancer 
Genome Atlas (TCGA) and The Genotype-Tissue Expression Project (GTEx) databases show 
that ASF1A and ASF1B are overexpressed in 20 and 24 different types of cancers, 
respectively, suggesting their widespread dysregulation in cancer development.  
Many studies have suggested ASF1s as crucial factors in carcinogenesis. We showed that 
ASF1A promoted gastrointestinal cancer pathogenesis by targeting β-catenin downstream 
genes. More recently, ASF1A has been found as an immunotherapeutic target in kras-mutant 
lung adenocarcinoma[126]. In addition, ASF1A is required for the constitutive expression of 
telomerase reverse transcriptase (TERT), which is essential for the immortal phenotype of 
cancer cells[127]. ASF1B was reported to accelerate breast cancer cell growth and to predict 
poor clinical outcomes [124, 125]. In clear cell renal cell carcinoma, ASF1B promoted 
cellular proliferation and migration [128]. Another study reported that prostate cancer (PCa) 
cells depleted of ASF1B underwent apoptosis resulting from the PI3K/Akt pathway 
inhibition [129].  
 
1.5 ASF1 AND CELLULAR SENESCENCE 
1.5.1 Cellular senescence 
Cellular senescence is described as a process where cells quit from cell cycle and undergo 
distinctive phenotypic alterations, including morphology, chromatin, transcriptome and 
secretome changes[130-133]. Other than functioning in embryonic development, host 
immunity, wound healing, tissue repair and organismal aging, cellular senescence is also 
important in tumor suppression[134]. It is reported that cellular senescence can repress a 
variety of cancers, such like breast cancer, hepatocellular carcinoma, gastric, prostate, 
colorectal, and lung cancer[134]. Typically, normal human cells undergo senescence rather 
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than transformation upon oncogene activation, which is so-called oncogene-induced 
senescence (OIS). In certain cases, cellular senescence is regarded more significant than other 
forms of cell death for tumor suppression in mammals, since evidence has shown that subtle 
perturbations in senescence regulatory network influence cancer susceptibility dramatically in 
mice while defects in apoptosis do not[134]. Thus, cellular senescence induction serves as a 
novel strategy for cancer treatment. 
1.5.2 The role of ASF1 in cellular senescence 
ASF1A has been shown to participate in the formation of Senescence-Associated 
Heterochromatin Foci (SAHF)[135, 136]. SAHF is the condensed transcriptionally silent 
heterochromatin region which is observed in senescent cell nuclei under certain 
circumstances[135]. In other cases, however, cellular senescence and SAHF formation are 
not always coupled. For example, SAHF is preferentially induced in OIS rather than in 
replicative cellular senescence[137]. Besides, SAHF formation depends on cell types[138]. 
We have reported that ASF1A knockdown in liver and prostate cancer cell lines carrying 
wild-type (wt) p53 induces growth arrest and senescence via activation of the DNA damage 
response (DDR)/p53/p21cip pathway[105]. 
 
1.6 SOLID TUMORS STUDIED IN THIS THESIS 
1.6.1 Gastrointestinal cancer (GIC) 
1.6.1.1 Epidemiology 
GIC is one of the most common malignancies and the leading cause of cancer-related death 
worldwide. In 2015, there were approximately 1,157,000 new cases of GIC and 798,500 
related deaths in China[139]. In USA, although GC incidence overall is low, colorectal 
cancer (CRC) incidence is high. In 2015, there were 132,700 new cases and 49,700 deaths 
caused by CRC in USA[140]. 
1.6.1.2 Etiology 
GIC can be triggered by genetic and environmental factors. Genomic instability and 
mutations have been reported in GIC[141]. GIC is more prevalent to be seen in developing 
countries like countries in east Asia. This phenomenon indicates that hygienic standards, 
eating habits and microbiota colonization may be associated with GIC development. Due to 
the daily exposure to the stimuli from food and microbiota, inflammation often occurs in the 
digestive tract. The function of inflammation is to resist infection, but persistent activation of 
inflammatory responses creates an enduring inflammatory microenvironment. This special 
microenvironment promotes tumor-favoring inflammation and finally leads to the unresolved 
inflammation which is regarded as a cancer hallmark[6, 142, 143]. 
1.6.1.3 Wnt/β-Catenin pathway in GIC 
The Wnt/β-Catenin pathway is a highly conserved pathway involved in development from 
nematodes to humans[144]. The central character of Wnt/β-Catenin pathway is β-Catenin 
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protein which is encoded by CTNNB1. β-Catenin can either function at the cellular adherent 
junctions by interacting with E-cadherin or present in the nucleus as a transcriptional 
factor[144]. When lacking upstream activating signals, β-Catenin is rapidly phosphorylated 
by a ‘destruction complex’ which is composed of AXIN, APC, GSK3, CK1, followed by 
proteasomal degradation[145]. Thus, β-Catenin has a very low cytosolic concentration in 
normal circumstance. In certain developmental situations, the Wnt ligand binds to the FZD 
receptor and LRP coreceptor, and recruits DVL and Axin to the cell membrane[144]. In this 
way the ‘destruction complex’ is disrupted and β-Catenin is released from phosphorylation 
and degradation. β-Catenin is then translocated into the cell nucleus and mainly interacts 
with the T-cell factor/lymphoid enhancer factor TCF/LEF transcription factors and initiates 
transcription of downstream genes[144]. 
The Wnt/β-Catenin pathway plays an important role in both intestinal development and CRC. 
It is reported that 90% of CRC tumors have mutations in key components of the Wnt/β-
Catenin pathway, most of which appear in APC or CTNNB1[146]. Especially, activation of 
the Wnt/β-Catenin pathway is highly associated with tumor metastasis in GIC. One important 
mechanism underlying the Wnt/β-Catenin pathway-mediated cancer metastasis is the 
epithelial to mesenchymal transition (EMT).  
1.6.2 Hepatocellular carcinoma (HCC) 
1.6.2.1 Epidemiology 
HCC is the most common liver cancer with high lethality, ranked as the sixth most common 
cancer and the third leading cause of cancer death in 2012[147]. Chronic liver disease has 
been indicated as an important trigger in HCC development[147]. HCC has been reported as 
a leading cause of death in cirrhosis patients[147]. Approximately 80% of HCC cases occur 
in sub-Saharan Africa and eastern Asia, which suggests a higher morbidity in less developed 
countries[147]. There is a higher incidence in men than in women[148]. 
1.6.2.2 Etiology 
HCC is usually caused from chronic liver diseases, such as chronic hepatitis B virus (HBV) 
infection, chronic hepatitis C virus (HCV) infection and cirrhosis[149]. In sub-Saharan Africa 
and eastern Asia, the main risk factors are chronic hepatitis B and aflatoxin B1 exposure, 
whereas in USA, Europe, and Japan, the main risk factor is hepatitis C and alcohol 
abuse[147].  
1.6.2.3 Genome instability and DDR in HCC 
HCC is thus highly associated with HBV and HCV infection[150-152]. HCV, an RNA virus, 
is not able to integrate into the host genome, while HBV is a DNA virus which is frequently 
inserted into the host genome and contributes to the carcinogenesis[153]. The integration of 
HBV into the liver cell genome is a risk factor to cause genome instability and DNA 
damage[150]. Interestingly, HBV has a locational preference to be integrated in regions 
crucial to genome stability such as CpG islands, chromosomal fragile fractions and regions 
adjacent to telomere in tumors [150]. The prevalent presence of DNA damage and 
chromosomal instability is an important feature of HCC[154]. 
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DDR refers to a series of reactions when cells encounter DNA damage usually caused by 
endogenous insults like ROS and replication errors or exogenous stimuli such as radiation 
and chemicals[155]. DNA damage can be divided into mainly two types: single-strand DNA 
breaks and double-strand DNA breaks. After a certain type of DNA damage happens, the cell 
cycle checkpoints usually at G1/S and G2/M boundaries are activated. The activation of 
checkpoints pauses the cell cycle progression and facilitates DDR. DNA damage sensation 
and checkpoint activation are controlled by two kinases which are also at the central position 
of the DDR: ataxia telangiectasia and Rad3-related (ATR) which reacts to single-strand DNA 
breaks or replication stress, and ataxia telangiectasia mutated (ATM) which responds to the 
more severe double-strand DNA breaks or disruptions in higher order chromatin[156]. ATR 
and ATM organize the downstream DDR cascades and result in either DNA damage repair or 
cell death/senescence. If the lesions on DNA are not so serious and are repairable, after the 
DNA repair process, the recovered cell will be released into the cell-cycle[156]. However, if 
there are sustained DNA damage signals, which indicates that the injured cell can be 
sacrificed, cell death or senescence program will be initiated. For example, ATR and ATM 
can activate p53 pathway and induce apoptosis or senescence[156]. 
1.6.2.4 p53 in the DDR 
p53 is a tumor suppressor and the most frequently mutated gene in cancer[157-159]. p53 
plays an important role in the DDR and thus is called the ‘guardian of the genome’. 
Following DNA damage, p53 regulates cell cycle arrest and is crucial for the cell fate[157]. 
The fate of the cells with DNA damage goes to survival (DNA repair), death (apoptosis) or 
senescence. p53 regulates a variety of biological functions including DDR, cell cycle arrest, 
apoptosis, senescence and metabolism[157]. 
1.6.3 Prostate Cancer (PCa) 
1.6.3.1 Epidemiology 
PCa is the most prevalent malignancy in men. The incidence increases with age, quite often 
to be diagnosed among men aged > 79 years[160]. It is more common in the western 
countries than in the east, indicating lifestyle and environment as risk factors.  
1.6.3.2 Etiology 
Both genetic and environmental factors affect PCa development. A family history of PCa is a 
crucial risk factor. It has been reported that men who have first-degree relatives with PCa 
have twice the risk for PCa compared to men in the general population. If the first-degree 
relatives with PCa are diagnosed below the age of 60 years, this increased familial risk is 
more than four times higher than that for men in the general population[161]. Smoking and 
alcohol consumption also increase the risk of PCa[160]. 
1.6.4 Adrenocortical Carcinoma (ACC) 
1.6.4.1 Epidemiology 
ACC is a rare endocrine cancer carrying a poor prognosis[162]. Different from the benign 
adrenocortical adenoma (ACA) which is prevalent in 3%-10% of the world’s population, 
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ACC only occurs in 0.7 - 2 persons per million[163, 164]. However, ACC is much more 
aggressive and malignant than ACA[165]. Patients with stage III/IV ACC only have a 
median survival of less than 1 year and the survival rate of patients with stage IV ACC is 
merely 6% - 13% at 5 years[164, 166]. Distinguishing ACC from ACA at presentation is very 
important for the further management. 
1.6.4.2 Etiology 
ACC is likely to be genetically predisposed and seems to be comparably more prevalent in 
children[163, 167, 168]. Germline TP53 mutations account for the relatively high incidence 
in childhood[169]. Generally, the molecular pathology of ACC includes abnormal clonality 
and DNA content, epigenetic changes, microRNA dysregulation and gene mutations. There 
are several forms of abnormal clonality and DNA content like aneuploidy, chromosomal 
aberrations such as chromosomal gains in 4q, 4p16, 5p15,9p34, 12q13,12q24 and 19p[170, 
171]. Epigenetic changes include DNA methylation on 11p15 which contains important 
genes IGF2 and H19[163]. MicroRNA dysregulation and gene mutations include genetic 
alterations in TP53, MEN1, IGF2 and CDKN2A[163]. Abnormal cellular signaling pathways 
also play an important role in ACC development, such as the IGF pathway, WNT pathway 
and vascular endothelial growth factor (VEGF) pathways[163]. 
1.6.4.3 The Weiss scoring system 
The Weiss scoring system is the most accepted pathological assessment standard for ACC in 
clinical practice[163, 165, 172]. The Weiss scoring system assesses 9 criteria which reflect 
the architectural, nuclear and invasion status of ACC tumors[165, 173-175] (Figure 6). Each 
item examined is ranked 0 if it is absent and ranked 1 if it is present in the tumor. The total 
Weiss score is a sum-up of the 9 sub-scores and is used to evaluate the aggressiveness of the 









2 AMIS OF THE STUDY 
 
The overall aim of this thesis was to increase the knowledge of the oncogenic role of histone 
chaperone proteins ASF1A and ASF1B in solid tumors and the underlying molecular 
mechanisms, especially of their novel functions other than the canonical role in assisting 
nucleosome assembly and disassembly, as well as their diagnostic and prognostic values. 
The specific aims of each study are:  
Paper I 
To explore the role of ASF1A in GIC and to determine the physical interaction between 
ASF1A and the oncogenic transcription factor β-Catenin and the impact on proliferation, 
stemness and migration/invasion on GIC cells. To evaluate the prognostic value of ASF1A in 
GIC patients. 
Paper II 
To define the effect of ASF1A on inducing p53 dependent cell cycle arrest and cellular 
senescence and the associated mechanisms in HCC and PCa. To assess the potential 
prognostic value of ASF1A in HCC patients. 
Paper III 
To evaluate the diagnostic and prognostic values of ASF1B in ACC and to explore the impact 







3.1 PATIENT SAMPLES (PAPERS I AND II)  
The 286 GIC patient samples in Paper I were collected at Qilu Hospital and Second Hospital 
of Shandong University, China. The 51 HCC patient samples and 29 non-tumorous adjacent 
liver tissues in Paper II were recruited from Qilu Hospital and Second Hospital of Shandong 
University, China. Surgical samples were collected from operations and were stored at -80 
freezer or in TRIzolTM Reagent or paraffin-embedded immediately. The studies were 
approved by the ethics committee of Second Hospital of Shandong University.  
3.2 CELL LINES AND CELL CULTURE (PAPERS I - III) 
GC cell lines AGS, BGC-823 and HGC-27, CRC cell lines HCT116, HCT116-Cas9 and 
HCT116 p53-/- sublines, SW480, Caco2 and HT29, HCC cell lines HepG2, Huh.7 and 
Hep3B, PCa cell line LNCaP, breast cancer cell line MCF-7, normal human umbilical-
derived mesenchymal stem cells (UMSCs), adrenocortical carcinoma cell line NCI-H295R 
and HEK-293T were used in Paper I – III. BGC-823, HGC-27, SW480, Caco2, HT29, 
HepG2, Hep3B, LNCaP and MCF-7 cells were cultured in RPMI-1640 medium with 10% 
fetal bovine serum (FBS), 100U/ml penicillin, 100ug/ml streptomycin and 4mM L-glutamine. 
AGS cells were cultured in F12 medium with 10% FBS, antibiotics and L-glutamine. HCT-
116 cells and the variants were cultured in Dulbecco’s modified Eagle’s medium supplied 
with 10% FBS and antibiotics. HEK-293T and Huh.7 cells were cultured in DMEM medium 
with 10% FBS, antibiotics and L-glutamine.  UMSCs were cultured in F12 medium with 
10% FBS, bFGF (10 ng/ml), antibiotics and L-glutamine. NCI-H295R cells were cultured in 
DMEM/F12 medium with 2.5% Nuserum and 1% Insulin-Transferrin-Selenium (ITS). All 
cells were incubated at 37 °C in a humidified atmosphere containing 5% CO2. 
3.3 RNA EXTRACTION AND QUANTITATIVE REAL-TIME PCR (QPCR) 
(PAPERS I - III) 
Total RNA was extracted from patient samples or cell lines using TRIzolTM Reagent liquid 
according to manufacturer’s instructions. RNA was then reversely transcribed into cDNA. 
qPCR was performed using SYBR green PCR Master Mix. Relative mRNA expression was 
presented in arbitrary units based on the CT values and normalized with β-2m expression. 
3.4 siRNA AND PLASMID TRANSFECTION (PAPERS I - II) 
ASF1A, β-Catenin, ZEB1, p53 and negative control siRNAs were commercially available 
and were reconstituted to the concentration of 20 nM as working solution after purchase. 
Cells were transfected with siRNA by using Lipofectamine 2000 or transfected with plasmids 
by using Lipofectamine 3000 in antibiotic-free Opti-MEM medium according to the 
manufacturer’s instruction.  
3.5 PROMOTER ACTIVITY ASSAY (PAPERS I - II) 
Wt E-cadherin promoter, E-box-mutated (E-box1 and 3) E-cadherin promoter and 
p21cip1/WAF1 promoter plasmids were obtained from Addgene (Middlesex, UK). The pGL3 
Basic luciferase reporter vector was purchased from Promega (Madison, WI, USA). Firefly 
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and Renilla luminescence was measured by using the Luciferase Assay (Promega). The 
Renilla luminescence activity was set for normalization. 
3.6 WESTERN BLOT (PAPERS I - III) 
Total protein was extracted from cell lines or patient samples by using RIPA lysis buffer 
[Cell Signaling Technology (CST)]. Samples were then loaded in Mini-PROTEAN TGX 
Gels (Bio-Rad, Hercules, CA, USA) and transferred to 0.2 um PVDF membranes (Bio-Rad). 
The membranes were blocked with 5% non-fat milk for 2 hrs at room temperature and then 
incubated with primary antibodies at 4 overnight with gentle shaking. The second antibodies 
were added the next day and the target proteins on the membranes were detected. β-Actin was 
used for normalization. 
3.7 SOUTHERN BLOT (PAPER II) 
Genomic DNA was extracted from cells using QIAamp DNA Blood Mini Kit (Cat no 51104, 
Qiagen, Hilden, Germany). Southern blot protocol was from Telo TAGGG Telomere Length 
Assay (Merck, Cat no. 12209136001). 
3.8 IMMUNOFLUORESCENCE (IF) STAINING (PAPERS I - II) 
Cells under different treatments were cultured on coverslips. Cells were fixed in 4% 
formaldehyde, washed with PBS and blocked in blocking buffer (Dako, Santa Clara, CA, 
USA) for 1 h. Primary antibodies were then added and incubated at 4 °C overnight. Triton-
100 (Sigma-Aldrich; St. Louis, MO, USA) was used to increase the permeability of cellular 
and nuclear membranes. The nuclei were stained with 4-6-diamidino-2-phenylindole 
dihydrochloride (Vector Laboratories Inc., Burlingame, CA, USA). 
3.9 COLONY-FORMATION ASSAY (PAPERS I - II) 
GIC, HCC and PCa cells under different treatments were seeded into 6-well plates at proper 
concentrations and incubated for 12 – 14 days in a humidified atmosphere containing 5% 
CO2 at 37 °C. The colonies were fixed with methanol and stained with Giemsa buffer. 
Colony numbers (colonies with > 50 cells) were then counted.  
3.10 FLOW CYTOMETRY AND CELL CYCLE ANALYSIS (PAPERS I - II) 
Flow cytometry was used for LGR5 staining in Paper I and cell cycle analysis in Paper I and 
Paper II. For LGR5 staining, cells were harvested, washed with PBS. After the blocking 
treatment, cells were incubated with the LGR5 primary antibody for 1 h at room temperature. 
The second antibody was then added for 1h incubation. Cells were then analyzed. For cell 
cycle analysis, cells were fixed in 70% ethanol at 4 ℃ overnight and stained with a solution 
containing RNase (0.5 μg) (Sigma - Aldrich) and propidium iodide (50 μg/ml) (Sigma - 
Aldrich). Cell cycle was analyzed using flow cytometry and further data analysis was 
performed by using ModFit (BD Biosciences, Franklin Lakes, NJ, USA) and Kaluza software 
(Beckman Coulter, Indianapolis, IN, USA). 
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3.11 β-GALACTOSIDASE (β-GAL) STAINING (PAPER II) 
β-Gal staining was used for the detection of cellular senescence in HCC and PCa cell lines in 
Paper II. Cells under different treatments were cultured for 8-10 days, rinse with PBS and 
fixed with 4% formaldehyde and incubated with freshly prepared β-Gal staining solution 
(Cellular Senescence Assay KAA002; Merck) at 37 °C overnight without CO2.  
3.12 MONO-SPHEROID FORMATION ASSAY (PAPER I) 
Cells were seeded and cultured in ultra-low-attachment 96-well plates in RPMI-1640/10 mM 
HEPES serum-free medium. Two types of growth factors were needed during the culture: 10 
ng/ml bFGF and 20 ng/ml EGF. The spheroid colonies formed in 15 days and were counted 
by using a light microscopy. 
3.13 MIGRATION AND INVASION ASSAY (PAPERS I AND III) 
Cells were seeded and cultured in serum-free medium in the upper chamber. For the 
migration assay, the lower chamber contained RPMI-1640 medium with 20% FBS for HGC-
27, HCT116, SW480 and HT29 cells in Paper I and DMEM/F12 medium with 5% Nuserum 
and 1% ITS for NCI-H295R cells in Paper III. Migrated cells were stained with crystal violet 
solution at proper time points and then photographed and quantified. For the invasion assay, 
50 μl Matrigel (Corning life sciences, Flintshire, UK) was injected into the bottom of the 
upper chamber and incubated for 1 h before cells were seeded. The following procedures 
were the same as in the migration assay. 
3.14 IMMUNOPRECIPITATION (IP) (PAPER I) 
IP protocol was based on the instruction of Pierce™ Crosslink Magnetic IP/Co-IP Kit 
(Thermo Fisher Scientific) which was used in the experiment. 50 μg protein extracts were 
incubated with IP antibodies at 4 °C overnight. The Protein A/G Magnetic Beads were then 
covalently crosslinked with the antibody using disuccinmidyl suberate. The antibody-
crosslinked beads were incubated with the interested protein-containing cell lysate of interest. 
Washing buffer was used to remove the non-specific unbound materials. Elution buffer was 
used for the clearance of bound antigen from the antibody-crosslinked beads. Neutralization 
buffer was used to prevent the precipitation of the isolated antigen. The precipitated product 
was loaded in Mini-PROTEAN TGX Gels for Western blot examination.  
3.15 CHROMATIN IMMUNOPRECIPITATION (CHIP) (PAPER I) 
The ChIP protocol was based on the instruction of SimpleChIP® Enzymatic Chromatin IP 
Kit (Magnetic Beads) (Cell Signaling Technology), which was used in the experiment. Cells 
under different treatments were crosslinked with formaldehyde. Micrococcal Nuclease was 
used for chromatin digestion and the products were analyzed by running agarose gels. DNA 
concentration was determined by Nanodrop 2000 (Thermo Fisher Scientific). The primary 
antibodies and positive control (histone H3) antibody were incubated with the digested 
products at 4 °C overnight with rotation. The DNA-antigen-antibody complex was 
precipitated with Protein G Magnetic beads. The chromatin was then eluted from 
Antibody/Protein G Magnetic Beads, followed by the reversal of cross-links. The DNA 
products were purified and amplified using PCR. 
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3.16 IMMUNOHISTOCHEMISTRY (IHC) (PAPER I) 
Paraffin embedded slides were deparaffinized and rehydrated. Citric acid buffer was used for 
antigen-retrieval and H2O2 was used for the deactivation of endogenous peroxidase. Ten 
percent of goat serum was used as blocking buffer. Slides were incubated with primary 
antibodies at 4 °C overnight. Second antibodies were added the second day and incubated for 
45 mins at room temperature. DAB staining was then carried out for the detection of the 
specific signals.  
3.17 ANIMAL EXPERIMENTS (PAPER I) 
The animal experiments in Paper I included subcutaneous tumor formation and metastasis of 
CRC cells in a murine xenograft model. For the subcutaneous tumor formation experiment, 
HT29 and HCT116 cells under different treatments were injected into six weeks old male 
nude mice subcutaneously (2 × 106 cells/mouse, 5 mice/group). Tumor size was measured 
weekly for 6 weeks and mice were then sacrificed. Tumors were separated and collected for 
further experiments and analysis. 
For the metastasis of CRC cells in the murine xenograft model, HT29 cells under different 
treatments were injected into six weeks old NOD-SCID mice via the tail vein (3×106 
cells/mouse, 6 mice/group). Mice were sacrificed after 7 weeks. The lungs were collected. 
Half of each lung was embedded with paraffin and the other half was immediately frozen at -
80 °C freezer for further experiments and analysis. 
3.18  LENTIVIRUS INFECTED STABLE CELL LINES (PAPERS I AND III) 
A plasmid cocktail including 15 μg viral vector, 10.5 μg sPAX2 vector and 6 μg pMD2.G 
plasmid was transfected into HEK293T cells which were cultured in a 75 cm2 flask at 90% 
confluency by using Lipofectamine 3000. Supernatants were collected at 48 hrs and 72 hrs 
after the transfection and was filtered through 0.45 μm filters. PEG-it TM Virus Precipitation 
Solution (System Biosciences, Palo Alto, CA, USA) was used for supernatant concentration 
(1 volume PEG-itTM Virus Precipitation Solution in 4 volumes viral supernatant). The 
mixture was stored at 4 °C overnight and centrifuged for virus pellets. The pellets were 
reconstituted with DMEM medium and HEPES buffer. The lentivirus was added to cells for 
infection at modified concentrations. Polybrene Infection/Transfection Reagent (Sigma-
Aldrich, St Louis, MO, USA) was used to improve the infection efficiency. Successfully 
infected cells were selected by using puromycin (Thermo Fisher Scientific) at different 
concentrations (HCT116 cells: 5 μg/ml; NCI-H295R cells: 10 μg/ml). 
3.19 CRISPR-CAS9 KNOCKOUT (KO) CELL LINES (PAPER II) 
CRISPR plasmids were transfected into cells using Lipofectamine TM 3000 Transfection 
Reagent (Thermo Fisher Scientific) according to the product instructions. Twenty-four – 48 
hrs after the transfection, when GFP fluorescence could be observed, GFP positive cells were 
sorted out and cultured. When the cell population grew to 90% confluence, the cells were 
digested by using 0.25% Trypsin (Thermo Fisher Scientific) and single cells were sorted into 




3.20 RNA SEQUENCING (RNA-SEQ) 
Total RNA was extracted form NC, siASF1A, siASF1B, siASF1A+siASF1B groups by using 
miRNeasy Mini Kit (Qiagen). RNA-seq was carried out on Illumina platform. Data were 
analyzed through R. 
3.21 DATA ANALYSIS FROM ONLINE DATABASES (PAPERS I - III) 
In Paper I, ASF1A mRNA expression values were related to prognosis of CRC patient 
survival and were downloaded from GEO datasets (http://www.prognoscan.org/) (GSE17536 
and GSE17537). The data for 32 colorectal adenoma and 32 normal mucosa samples were 
obtained from GEO (GSE8671) and analyzed via GEO2R. Data for progressive colorectal 
diseases, including adenoma (17 samples), carcinoma (17 samples) and carcinoma with 
metastasis (11 samples) were downloaded from GEO (GSE77953). The data of 211 primary 
CRC samples for gene expression correlation analyses were from GEO (GSE75315).  
In Paper II, data of ASF1A mRNA expression in HCC, PCa, GC and BC and their normal 
tissue counterparts were obtained from TCGA (https://cancergenome.nih.gov) and GTEx 
(https://gtexportal.org/home/) databases. Data of ASF1A and p21cip1 expression from TCGA 
used above were downloaded via cBioPortal (http://www.cbioportal.org) (January, 2018). 
ASF1A and p21cip1 survival analysis using TCGA data was achieved by GEPIA 
(http://gepia.cancer-pku.cn). 
In Paper III, TCGA data of ACC samples were downloaded via UCSC-Xena 
(http://xena.ucsc.edu, March, 2020) and cBioPortal (https://www.cbioportal.org, March, 
2020). 
3.22 STATISTICAL ANALYSES (PAPERS I - III) 
Experimental quantitative data in Paper I, II and III were obtained from biological replicates 
and shown as means ± standard deviation (mean ± SD) if not otherwise indicated. Student’s 
t test (two-tailed) was applied to examine the differences between experiment groups. 
Disease-free survival (DFS) and overall survival (OS) were visualized by Kaplan–Meier 






4.1 PAPER I: ASF1A IN GIC PROGRESSION  
4.1.1 ASF1A overexpression in GIC cell lines/primary tumors  
As there were not many reports on the expression of ASF1A in human cancers, especially it 
was vacant in GIC, we first examined ASF1A expression in several GIC cell lines including 
GC derived cell lines AGS, BGC-823 and HCG-27 and CRC-derived cell lines HCT116, 
SW480, HT29 and Caco-2 (Figure 7A). The results revealed that ASF1A had the most 
abundant expression in the most aggressive or poorly differentiated GC cell line HGC-27 and 
CRC cell line HCT-116. We then evaluated ASF1A expression in primary GIC tumors and 
their adjacent non-tumorous (NT) counterparts from 286 GIC patients (106 GC and 180 CRC 
patients) by performing IHC staining and found that ASF1A had a significant higher 
expression in GIC tumors compared with the NT tissues (GC vs NT, CC vs NT and rectal 
cancer (RC) vs NT) (Figure 7B and C). Interestingly, ASF1A expression increased orderly in 
normal, metaplasia and cancer tissues in gastric sections. These findings collectively 





4.1.2 The interaction between ASF1A and β-Catenin 
To investigate ASF1A’s function in GIC cells, we used CRC cell line HT29 which had very 
low basal ASF1A expression to generate ASF1A stable overexpression sublines (HT29-
Figure 7. ASF1A overexpression is observed in GIC cell lines/primary tumors and is associated with 
the evolution of GIC.  (A) ASF1A protein expression in GIC cell lines. (B) Quantification of 7C showing 
the percentage of ASF1A positive cells in tumors and their non-tumorous (NT) counterparts. (C) 
immunohistochemistry (IHC) staining of ASF1A in primary GIC tumors and their NT counterparts. 
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ASF1A) with the aid of lentivirus system. HT29-ASF1A cells had higher ASF1A expression 
on protein level and accumulated histone H3K56 acetylation. Cell cycle analysis showed 
significant declines in G1 phase and increases in S phase in HT29-ASF1A cells compared 
with control cells. Colony formation assays exhibited a higher colony formation ability of 
HT29-ASF1A cells than control cells. ASF1A overexpression was also associated with 
stemness and migration/invasion ability. We examined the CRC stem cell marker Lgr5 using 
flow cytometry and found a higher Lgr5 expression in HT29-ASF1A cells than in control 
cells. An increase in sphere formation ability was observed in ASF1A overexpressing cells, 
which also indicated the enhanced stemness of HT29-ASF1A cells. Increased migration 
ability was shown in ASF1A overexpressing HT29 cells by using a Transwell assay. 
Knockdown of ASF1A using siRNAs in ASF1A high expressing GIC cell lines HGC-27, 
HCT116 and SW480 led to significantly impaired migration and invasion ability in all the 
three cell lines. Cellular morphology examination showed less elongated or spindle-like 
shapes in ASF1A-depleted cells, which was a feature more prevalent in epithelial cells than in 
mesenchymal cells. These functional studies together revealed the effect of ASF1A in 
facilitating proliferation, stemness and migration/invasion ability in GIC cells.  
Because the Wnt/β-Catenin pathway alteration was an important cause of the GIC 
pathogenesis, we examined the potential connection between ASF1A and β-Catenin. First, 
we found a physical interaction between ASF1A and β-Catenin proteins using IP (Figure 
8A). We then introduced a TCF/LEF assay to evaluate the impact of the observed interaction 
on β-Catenin’s function. The TCF/LEF assay was designed to measure the transcription 
activity of β-Catenin. We validated the efficiency of the TCF/LEF assay by transfecting β-
Catenin expression plasmids into HCT116 cells and found an elevated reporter activity in 
these cells. Synchronous transfection of β-Catenin and ASF1A expression plasmids showed 
enhanced reporter activity in a synergistic manner. Thus, ASF1A boosted the transcriptional 







Figure 8. ASF1A physically interacts with β-Catenin and activates the β-Catenin target promoters.  
(A) Immunoprecipitation (IP) showed a physical interaction between ASF1A and β-Catenin proteins. (B) 
TCL/LEF reporter activity is regulated by ASF1A. In HCT116 cells, β-Catenin overexpression can increase 
TCL/LEF reporter activity. Overexpression of both β-Catenin and ASF1A amplifies this effect. 
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Combined with the functional study, we investigated whether the ASF1A/ β-Catenin 
interaction could explain the mechanisms behind the effects of ASF1A on proliferation, 
stemness and migration/invasion. We focused on several important β-Catenin target genes 
including LGR5, CCND1, c-MYC and ZEB1, and determined CCND1, c-MYC and ZEB1 
expression at mRNA and protein levels in control and HT29-ASF1A cells. The results 
showed accumulated expression of the target genes in ASF1A overexpressing cells. 
Oppositely, depletion of ASF1A with siRNAs in HCT116 cells displayed decreased 
expression of CCND1, c-MYC and ZEB. By analyzing data of 210 patients in the GEO 
database, positive correlations could be drawn between ASF1A and CCND1, c-MYC or 
ZEB1, respectively. To further validate the activity of ASF1A on β -Catenin targeted 
promoters, ChIP assay was performed in HCT116 cells which had abundant endogenous 
expression of both ASF1A and β-Catenin. The results showed the enrichment of both 
ASF1A and β-Catenin on the promoter regions of CCND1, c-MYC and ZEB1. These 
findings demonstrated the amplifying function of ASF1A on the β-Catenin transcription 
activity, thereby promoting the malignant phenotypes of GIC. 
Because losing the epithelial marker E-Cadherin is a key process for increasing cell mobility 
and ZEB1 impairs E-Cadherin expression, we hypothesized that the ASF1A/ β -
Catenin/ZEB1 axis might promote invasion by inhibiting E-Cadherin expression. To verify 
this hypothesis, first, we knocked down ASF1A in HCT116 cells and observed accumulation 
of E-Cadherin and diminished ZEB1 expression at both mRNA level and protein levels. In 
contrast, overexpression of ASF1A in HT29 cells induced ZEB1 expression and decreased E-
Cadherin expression. Knockdown of β -Catenin in ASF1A overexpressing HT29 cells 
abolished ASF1A’s effect on ZEB1 and E-Cadherin. Inhibition of ZEB1 also led to the 
recovery of E-Cadherin. Since it is well documented that ZEB1 regulates E-Cadherin by 
binding to the E-boxes in the promoter region of E-Cadherin, we evaluated the E-Cadherin 
promoter activity in ASF1A-depleted HCT116 cells. We found that E-Cadherin promoter 
activity was upregulated in ASF1A-inhibited HCT116 cells while mutation on E-boxes could 
attenuate the effect. 
4.1.3 ASF1A effects on GIC in mouse xenograft models 
To examine the effects of ASF1A on proliferation in GIC in vivo, we injected control 
HT29/HT29-ASF1A cells, and control HCT116/HCT116-ASF1AshRNA cells 
subcutaneously into 6 week old nude mice, respectively. Mice were sacrificed after 6 weeks. 
Tumor volume was recorded during this period weekly. The HT29-ASF1A tumors grew 
much faster and were bigger than the control ones, while the HCT116-ASF1A sh tumors 
grow slower and were smaller than their control counterparts. IHC staining showed stronger 
ASF1A, E-cadherin and PCNA signals in HT29-ASF1A tumor slides than in the control 
sections, whereas weaker signals were observed in HCT116-ASF1A-shRNA tumor sections 
than in control ones. 
For the in vivo metastasis experiments, we injected control HT29 and HT29-ASF1A cells into 
6 weeks old NOD-SCID mice via the tail vein. Mice were killed after 7 weeks. Metastatic 
lung tumors were quantified. The results showed that the control HT29 cells led to a total of 
19 metastatic nodules in the lungs while the HT29-ASF1A cells caused a total of 93 
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metastatic lung nodules. Besides, the tumor nodules in HT29-ASF1A group were generally 
larger than those in the HT29 control group. IHC staining revealed more intense ASF1A and 
PCNA signals while reduced E-Cadherin expression in tumors with ASF1A overexpression. 
Taking together, ASF1A promoted in vivo tumor growth and metastasis, which was in 
accordance with the results obtained from the in vitro experiments. 
4.1.4 The prognostic value of ASF1A overexpression in CRC patients 
The prognostic value of ASF1A in CRC patients was examined by using Kaplan-Meier 
analysis. A cut-off of 35% based on the proportion of ASF1A positive tumor cells in CRC 
IHC staining was set to define low (<35%) and high (>35%) ASF1A expressing 
tumors/patients. The results displayed that higher ASF1A expression predicted shorter OS 
sometimes in both colon cancer (CC) and rectal cancer (RC) patients. Further validation of 
ASF1A overexpression in CRC patients and its prognostic potential was carried out by GEO 
data analyses. The results showed that ASF1A was over-expressed in adenomas compared 
with normal intestinal mucosa, and in a small cohort of patients (n = 17), ASF1A was 
observed to have a gradual accumulation in adenomas, CRC and CRC with liver metastasis. 
Kaplan-Meier analysis further consolidated the association between higher ASF1A 
expression and shorter patient OS in two CRC patient cohorts (Cohort 1: n = 49; Cohort 2: n 
= 177). These results confirm the prognostic value of ASF1A in CRC patients. 














Figure 9. Work model for ASF1A mediated oncogenesis in CRC. ASF1A physically interacts with β-
Catenin and they synergistically promote β-Catenin downstream genes CCND1, MYC, LGR5 and ZEB1 
expression. Overactivation of these genes leads to GIC development and progression. 
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4.2 PAPER II: ASF1A INHIBITION-INDUCED SENESCENCE IN WT P53 
CARRYING CANCER CELLS  
4.2.1 ASF1A overexpression in multiple solid tumors with the prognostic 
value 
We first found that ASF1A was overexpressed in primary HCC tumors compared to their 
non-tumorous counterparts at both mRNA and protein levels. This finding was supported by 
the data from TCGA and GTEx databases. Apart from liver cancer, ASF1A expression was 
also increased in PCa, GC and BC based on TCGA and GTEx data. In addition, higher 
ASF1A mRNA expression predicted a worse OS and DFS in TCGA HCC patients, which 
supported ASF1A’s potential as a predictor of outcome. 
4.2.2 ASF1A knockdown-induced senescence in wt p53 carrying HCC and 
PCa cells 
To investigate the functions of ASF1A, we knocked down ASF1A using siRNAs in the HCC 
cell line HepG2 and PCa cell line LNCaP. Proliferation was the first parameter variable we 
assessed. We discovered that the ASF1A-depleted cells had a lower proliferation rate than the 
control cells. Colony formation assay showed decreased colonies in ASF1A knockdown cells 
than control ones in both HepG2 and LNCaP cells, indicating a weaker clonogenic ability. 
Cell cycle analysis revealed an accumulation in G0/G1 phase and a reduction in G2/M phase 
in both cell lines, which exhibited a cell cycle arrest phenotype (Figure 10A). 
Morphologically, the ASF1A depleted cells were generally bigger and flatter than the control 
cells, which was an indicator of cellular senescence. We then used β-Gal staining to validate 
the senescence phenotype in HepG2 and LNCaP cells. The results showed higher β-Gal-
positive (blue) staining in ASF1A-depleted HepG2 and LNCaP cells, which verified our 
hypothesis that ASF1A knockdown induced cellular senescence (Figure 10B and C). 
Notably, both HepG2 and LNCaP were wt p53-carrying cell lines. Because cellular 
senescence is in general triggered via the activation of p53-p21cip1 and/or p16 pathways, we 
questioned whether the ASF1A inhibition-mediated cellular senescence also happened in 
cells with defective p53. To this end, we introduced p53 mutant HCC cell line Huh.7 and p53 
null HCC cell line Hep3B, and knocked down ASF1A in these cell lines. We did not observe 
any significant cellular senescence phenotype in ASF1A-depleted Huh.7 and Hep3B cells, as 
seen in HepG2 and LNCaP cells. These findings demonstrated the effect of ASF1A inhibition 
on cellular senescence in wt p53-carrying cell lines HepG2 and LNCaP. 
4.2.3 ASF1A inhibition-induced senescence and the DDR/p53/p21cip1 
pathway 
To further elucidate the mechanism underlying the p53-dependent growth arrest and 
senescence, we first performed a screen to check the mRNA expression of several cellular 
senescence-related genes: p16ink4a, p21cip1, p27kip1 and TERT in control and ASF1A 
knockdown HepG2 and LNCaP cells. The result showed that only p21cip1 was upregulated in 
ASF1A-inhibited cells. It is well documented that p21cip is transcriptionally regulated by p53, 
which was accordant with the findings above showing that the cellular senescence phenotype 
occurred in wt p53 cell lines HepG2 and LNCaP rather than p53 defective cell lines Huh.7 
and Hep3B. We then knocked down ASF1A using siRNAs in HepG2, LNCaP, AGS and 
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MCF-7 cell lines, all of which carried wt p53, and examined p53 and p21cip1 expression. 
Western blot and qPCR results revealed both p53 and p21cip1 to be upregulated in all the four 
cell lines upon ASF1 knockdown. We then introduced p53 binding site-containing p21cip1 
promoter plasmid. We found elevated p21cip1 promoter activity in ASF1A knockdown groups 
compared with control groups in both HepG2 and LNCaP cells. Interestingly, when we 
knocked down both ASF1A and p53 using siRNAs, the p21cip1 upregulation caused by 
ASF1A inhibition was attenuated, indicating the role of p53 in ASF1A depletion-mediated 
p21cip1 overexpression. To further validate the p53-p21cip1 mechanism, we knocked down 
ASF1A in Huh.7 and Hep3B cells and did not observed any p53 or p21cip1 accumulation. 
Luciferase assay also did not show higher p21cip1 promoter activity in ASF1A-inhibited cells. 
We knocked down ASF1A in wt p53-baring HCT116 cells and observed upregulation of both 
p53 and p21cip. Then we introduced p53 KO HCT116 sublines constructed by using CRISPR-
Cas9 system. We found that inhibition of ASF1A in p53 KO HCT116 cells was not able to 
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Figure 10. Knockdown of ASF1A induces growth arrest and cellular senescence in wt p53 carrying 
HCC and PCa cells. (A) Cell cycle analysis reveals that ASF1A knockdown induces a G0/G1 phase arrest 
and a reduction in G2/M phase in HepG2 and LNCaP cells. (B)  β-Gal staining shows that ASF1A inhibition 
leads to cellular senescence. (C) Quantification of 10B. The percentages of β-Gal staining-positive HepG2 
and LNCaP cells in different experimental groups are presented in bar charts. 
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Because p53 accumulation in general is caused by DDR, we questioned whether it was DDR 
induced by ASF1A depletion that triggered p53 activation. So we stained two DDR specific 
markers γH2AX and 53BP1 using IF staining. Our findings showed DDR foci in ASF1A 
knockdown HepG2 and LNCaP cells. These results collectively demonstrate the role of  
DDR/p53/p21cip1 pathway in ASF1A inhibition-mediated  cellular senescence. 















Figure 11. Graphic illustration of the tentative mechanism of the ASF1A inhibition induced cellular 
senescence. ASF1A inhibition causes growth arrest and cellular senescence in wt p53 carrying cancer cells 
through the DDR/p53/p21cip1 pathway. 
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4.3 PAPER III: THE DIAGNOSTIC AND PROGNOSTIC VALUES OF ASF1B 
AND ITS ASSOCIATION WITH METASTASIS IN ACC  
4.3.1 A higher copy number of the ASF1B gene and ASF1B mRNA 
overexpression in the TCGA cohort of ACC patients 
There are a lot of chromosomal aberrations presented in ACC. The TCGA cohort of ACC 
analysis revealed that chromosome 19p13.12, where the ASF1B gene is resident, had 
amplification. Analysis of ASF1B copy number variation (CNV) showed gain/amplification 
of ASF1B gene in 63.16% patients of the TCGA ACC cohort. ASF1B was overexpressed in 
TCGA ACC tumors on the mRNA level. By comparing ASF1B mRNA expression in ASF1B 
gene diploid tumors and ASF1B gene gain/amplification tumors, we found that ASF1B had 
higher expression in ASF1B gene gain/amplification tumors than did the diploid ones, which 
indicated that increased ASF1B gene copy numbers caused higher ASF1B expression. In 
summary, more than 60% of ACC tumors had ASF1B gains/amplification and this CNV 
resulted in increased ASF1B expression. 
4.3.2 The association between ASF1B alterations and Weiss scoring system 
criteria 
Weiss scoring system is the universally applied clinical diagnostic standard for ACC in the 
clinic. It examines 9 criteria which pinpoint the architectural, nuclear and invasion features of 
ACC tumors. By analyzing the TCGA ACC tumors, we found that ASF1B was associated 
with 7 criteria of the Weiss scoring system. Higher ASF1B expression was associated with 
necrosis, higher mitoses count, higher mitotic rate, higher nuclear grade, atypical mitoses and 
higher invasion ability including capsule invasion, sinusoid invasion and venous invasion. 
We could also see that tumors with a more abundant ASF1B expression had a higher Weiss 
score, which indicated a more malignant status. 
4.3.3 The correlation between ASF1B expression and ACC tumor stage & 
patient survival 
Tumor stage is an important prognostic indicator. Patients with stage III/IV ACC tumors 
frequently have metastatic disease and have a poor outcome. We found that ASF1B had 
higher expression in stage III/IV TCGA ACC tumors than in stage I/II tumors (Figure 12 A 
and B). Patients were divided into high and low ASF1B expression groups based on a cut off 
0.5. Survival analysis showed that ACC patients with higher ASF1B expression had a poorer 
OS and DFS, confirming the prognostic value of ASF1B in ACC (Figure 12C and D). 
4.3.4 The effect of ASF1B on ACC cell migration and invasion via FOXM1 
Because ASF1B was highly expressed in stage III/IV tumors which carrying a higher 
metastatic potential, we evaluated the effect of ASF1B on migration and invasion in the ACC 
cell line NCI-H295R. ASF1B knockdown and overexpression stable sublines were made with 
the aid of a lentivirus system. Results from the migration and invasion assay showed that 
ASF1B inhibition impaired both the migration and invasion capacity while overexpression of 










We then worked on the mechanisms behind the migration/invasion-promoting effect of 
ASF1B. By Analyzing the TCGA ACC transcriptome data, we found that FOXM1, which 
played an important role in regulating migration and invasion, was among the top genes that 
correlated with ASF1B expression. Western blot results showed diminished FOXM1 
expression in ASF1B knockdown NCI-H295R sublines as compared to control cells. 
Oppositely, ASF1B overexpressing NCI-H295R cells led to an elevated FOXM1 expression. 
These findings suggest that ASF1B boosted the migration/invasion ability of ACC cells 

































































































































































































Figure 12. ASF1B expression correlates with ACC tumor stage and patient survival. (A) ASF1B 
mRNA expression in stage I/II/III/IV TCGA ACC tumors. (B) ASF1B has a higher expression in stage III 
and IV ACC tumors than in stage I and II ACC tumors. (C) Patients with higher ASF1B expression have a 






5.1 ASF1 IN CANCER: THE CANONICAL ROLE AND BEYOND 
Both ASF1A and ASF1B are highly expressed in a variety of cancers based on the TCGA 
dataset analysis, suggesting their role in carcinogenesis. Both of the two paralogs are deeply 
involved in regulating rapidly dividing cancer cells and the actively transcribed cancer 
genome. As introduced above, ASF1A and ASF1B share the conserved duty of being a 
histone H3-H4 chaperone for histone transport[125]. Meanwhile, they also have divergent 
and novel functions in cancer pathogenesis and other biological processes. Due to the priority 
that ASF1A and ASF1B physically interact with histone H3/H4, they are ones of the most 
ideal candidates to deliver epigenetic information during DNA and chromatin metabolism. 
For example, Gao and colleagues reported that the ASF1A-histone interaction is required for 
transcription regulation by modifying histone H3K56 instead of the role of ASF1A in 
nucleosome assembly[176]. Thus, exploring the novel role of ASF1 and other histone 
chaperones in DNA and chromatin dynamics will provide new momentum to cancer 
epigenetic research. 
ASF1A or ASF1B deletion results in a distinct cell fate. In a study published in 2010, 
Corpet and colleagues knocked down ASF1A, ASF1B and ASF1A+ASF1B in human U-2-
OS cells and performed transcriptome analysis[125]. The results from GO analysis revealed 
distinct transcriptional signatures in the three experimental groups. The most affected cellular 
process in the ASF1A inhibition group was Cytokinesis, while ASF1B deletion highly 
influenced the DNA replication and G1/S transition of mitotic cells. There is an overlap 
between the genes altered by ASF1A or ASF1B knockdown. They also discovered that 
ASF1B knockdown induced abnormal cell nucleus, macronucleus and DNA bridges which 
were typical phenotypes of genome instability in the breast cancer cell line Hs578T. 
However, these phenomena were not found in ASF1A-depleted Hs578T cells. Besides, they 
noticed a potential compensation effect between ASF1A and ASF1B by observing a slight 
upregulation of ASF1A in ASF1B-inhibited U-2-OS cells. But they did not find any ASF1B 
increase in ASF1A knockdown cells. We also performed similar experiments in the PCa cell 
line LNCaP. We knocked down ASF1A, ASF1B and ASF1A+ASF1B respectively in LNCaP 
by using siRNAs and did RNA-seq. Our pathway analysis suggested that apart from some 
common functions ASF1A and ASF1B shared, they behaved differently in a variety of 
pathways, which was similar to the GO analysis in Armelle’s paper (Figure 12A). In a still 
unpublished study, we made ASF1B CRISPR-Cas9 KO sublines in the lung cancer cell lines 
A549 and NCI-H1299. Interestingly, we observed the similar nuclear abnormalities in 
ASF1B KO cells as seen in the study described above, which confirmed that ASF1B deletion 
heavily affected genome stability. However, results from our ASF1B CRISPR-Cas9 KO 
experiments in lung cancer cell lines A549 and NCI-H1299 showed that ASF1A expression 
did not increase significantly in ASF1B KO cells (Figure 12B). Furthermore, in the ASF1B 
overexpressing lung cancer cell lines A549, NCI-H1299, NCI-H1975 and ACC cell line NCI-
H295R, only little changes in ASF1A protein expression were detected either (Figure 12B). 
In the ASF1A or ASF1B knockdown LNCaP cells, an around 20% ASF1A mRNA increase 
was observed in ASF1B-inhibited cells while no significant ASF1B fluctuation was seen in 
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ASF1A-depleted cells. These observations suggested little or very low compensatory effect 






In summary, based on our findings and those from us and others, we conclude that single 
inhibition of the ASF1A or ASF1B paralog in cancer cells may cause distinct phenotypes and 
transcriptional signatures leading to different cell fate which mainly include proliferation 
inhibition, cell cycle arrest, apoptosis or senescence under multiple and complex cellular 
environments. ASF1A and ASF1B should be redundant in their overlapped duty in cancer 
cells so that there is little or weak compensation observed between them. Meanwhile, they 
might be quite independent from each other in their distinct roles. Further studies elucidating 
the different functions of ASF1A and ASF1B in cancer development and the underlying 
mechanisms will be necessary for precision oncology application. 
Figure 13. ASF1B and ASF1B have distinct functions other than their shared duty. (A) Pathway 
analysis of ASF1A and ASF1B-depleted LNCaP cells. (B) ASF1A and ASF1B protein expression in wild 
type and ASF1B knockout A549 and NCI-H1299 cells (the upper panel). ASF1A and ASF1B protein 




The divergence in ASF1A and ASF1B functions can be explained on a structural basis. 
As described in the introduction, ASF1A and ASF1B follow distinct evolutionary paths since 
some time point[107]. The structures of the two paralogs vary mainly in the C-terminus while 
they have a conserved core region and N-terminus. The structural difference may account for 
the functional divergence of ASF1A and ASF1B. Both ASF1A and ASF1B interact with 
CAF-1, though ASF1B has a much higher affinity than ASF1A[107]. However, only ASF1A 
binds to HIRA, which is involved in replication-independent nucleosome assembly and 
disassembly. This preference for the interaction with difference downstream chaperone 
partners is consistent with the major role of ASF1A in transcription regulation or DNA repair 
whereas ASF1B is involved in proliferation. In Paper I and Paper II, we reported that ASF1A 
acted as a transcriptional co-factor promoting β-catenin downstream gene expression and 
induce cellular senescence by triggering DDR/p53/p21cip pathway. In a study published in 
2014, Gonzalez-Muñoz and colleagues reported that ASF1A activated the expression of core 
pluripotency genes by acetylating histone H3K56[122]. Zhang and colleagues found that that 
ASF1 facilitated H3K56 acetylation by stabilizing the very C-terminal β strand of histone 
H4 and unwinding of the K56 located histone H3 αN, further unveiling the structural 
fundament of ASF1 function[177]. These findings may provide some clues on why and how 
ASF1A and ASF1B exert their specific functions under specific contexts and inspire future 
research on the more detailed mechanisms of how ASF1 and other histone chaperones behave 
in chromatin dynamics during replication, transcription and DNA repair. 
5.2 POSSIBLE MECHANISMS OF HOW ASF1 PROTEINS PARTICIPATE IN 
GENE EXPRESSION REGULATION 
Based on the limited publications on ASF1 proteins in transcription regulation and our 
research, we conclude that ASF1 proteins function in regulating gene expression in the 
following ways: 
ASF1 proteins interact with transcriptional factors/co-factors. In Paper I, we showed that 
ASF1A physically interacted with transcriptional co-factor β-Catenin and promoted the 
downstream gene expression in GIC.  Gao and colleagues found that ASF1A was recruited to 
some bivalent promoters in part by associating with transcription factors such as Nanog and 
Oct4 and trigger lineage specific gene expression in mouse embryonic stem cell (ESC) 
differentiation[176]. Another paper reported that ASF1B interacted with transcriptional 
coactivator HCF-1 and facilitated the herpes simplex virus (HSV) DNA replication and early 
gene expression[178]. Thus, ASF1 proteins may have the ability to selectively combine with 
specific transcriptional co-factors or transcription factors to increase the promoter activity and 
induce downstream gene expression.  
ASF1 proteins interact with histone H3/H4 and recruit enzymes for histone 
modification. ASF1A has been shown to induce core pluripotency genes by facilitating 
histone H3K56 acetylation[122]. In Paper I, we also detected decreased H3K56 expression in 
ASF1A inhibition GIC cells which showed impaired ability of proliferation, stemness and 
invasion. Hereby, ASF1 may serve as a linker protein to connect the transcription 
factors/cofactors, histone H3/H4 and histone modification enzymes, facilitating these factors 
to form a complex to finally mark the histones at the certain promoter region with specific 
histone modifications such as H3K56 acetylation. It was reported that histone H3K56 
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acetylation increased chromatin accessibility by driving chromatin toward the disassembled 
state during transcription activation[121]. Besides, ASF1 also promotes the histone 
disassembly process in these regions. Thus, ASF1 proteins may affect gene expression 
through promoting the communication between DNA elements and the chromatin 
environment in the regulatory regions to create a more opened chromatin state for 
transcription machineries. In addition, different from the downstream histone chaperone 
CAF-1 and HIRA that also interact with the replication and transcription machineries, ASF1 
proteins may have more freedom and less complexity in the regulating processes. 
There are still many questions to be answered. Which types of transfection factors/co-factors 
do ASF1 proteins prefer to bind? Which kinds of genes are regulated by ASF1 proteins? Is 
there any “reader” function of ASF1 proteins? Are there any other histone metabolisms in 
which ASF1 proteins are involved? How about the roles of other histone chaperones? Some 
studies have provided a few of clues. For instance, Clément and colleagues observed that 
H3K36me3 and H3K9me3 histone marks decreased in volume or density in ASF1-depleted 
cells by using super-resolution microscopy[179]. More research is required to further 
elucidate these unresolved questions. 
5.3 ASF1 IN CELLULAR SENESCENCE 
The role of ASF1 in cellular senescence has been studied and discussed in many publications, 
most of which mentioned the SAHF. SAHF refers to the phenomenon that the euchromatin 
regions containing proliferation-promoting genes are compacted into transcriptionally silent 
heterochromatin under cellular senescence state[135, 180-182]. Both ASF1A and HIRA are 
required to form SAHF[135, 136]. In Paper II, we discovered that ASF1A inhibition induced 
cellular senescence and did not find SAHF formation in ASF1A knockdown cells, which was 
in contrast with the previous findings of the presence of SAHF triggered by senescence. It is 
reasonable that cellular senescence and SAHF formation are not always coupled. First, 
whether SAHF can form is dependent on cell types[138]. For instance, SAHF is present in 
the senescent human embryonic fibroblast cell lines IMR90 and WI38 but is not observed in 
the primary human foreskin fibroblast cell line BJ[180]. Besides, SAHF formation favors to 
be fueled by the p16ink4 pathway which is usually activated by OIS rather than the 
DDR/p53/p21cip1 pathway induced by replicative cellular senescence[137].  In addition, 
TERT expression and telomerase activation is important for cancer cells to escape cellular 
senescence and become immortalized[183]. ASF1A inhibition was shown to decrease TERT 
expression, which impairs cancer cells’ ability to overcome senescence. In Paper II, however, 
we did not observe significant changes in TERT expression and telomere length in ASF1A-
inhibited HepG2 and LNCaP cells. Thus, the cellular senescence induced by ASF1A 
inhibition should not be caused by reduced TERT/telomerase or shortened telomere length. 
Cellular senescence is considered more important than cell death for tumor repression under 
certain circumstances. For example, the susceptibility of cancer in mice is heavily affected by 
senescence regulatory network rather than deficiency in apoptosis[134]. Thereby, targeting 
cellular senescence associated genes may be an efficient strategy for cancer treatment. 
Further evaluation of the ASF1A-depletion induced senescence may provide a fundamental 
basis for clinical intervention design and novel drug discovery. 
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5.4 ASF1 IN DNA DAMAGE AND GENOME INSTABILITY 
In Paper II, we found that ASF1A inhibition triggered DDR and activated sustained 
p53/p21cip1 pathway, finally inducing cellular senescence. ASF1A’s role in DNA repair has 
been well documented: ASF1A-mediated acetylation of histone H3K56 is necessary for DNA 
repair by participating in nucleosome reassembly in DNA damage repair process[113]. ASF1 
promotes checkpoint recovery after DDR[114]. The involvement of  ASF1A and ATM is 
important for UV-induced cell-cycle checkpoint recovery[115]. To be noted, ASF1A directly 
takes part in DNA double-strand break repair, which is a non-canonical role of ASF1A as a 
histone chaperone[116]. It is also reported that ASF1A is required for 53BP1 accumulation at 
the DNA damage region and in DNA damage situation, less 53BP1 foci are observed in 
ASF1A-inhibited U2OS cells compared with the control cells[116]. Oppositely, in Paper II, 
more 53BP1 foci were detected in ASF1A knockdown HepG2 and LNCaP cells than in 
control cells. This result may be accounted by the different ASF1A-associated DNA repair 
mechanisms under different contexts such as different cell lines with distinct ASF1A 
expression or genetic backgrounds. Collectively, based on the documented role of ASF1A in 
DNA repair, it is conceivable that ASF1A is a necessary factor involved in a range of cases of 
DNA repair processes. ASF1A inhibition may result in an impaired DNA damage repair 
outcome and lead to a sustained unresolved DNA damage state, which persistently activates 
p53/p21cip1 pathway and eventually arrests cell cycle and drives cell fate to cellular 
senescence. 
DNA damage is one form of genome instability, an important hallmark of cancer. 
Interestingly, in addition to the role of ASF1A in DNA repair, ASF1B may also contribute to 
protection of genome stability. As described above, ASF1B depletion caused nuclear 
abnormalities in several cancer cell lines[125]. There are also clues from our studies that 
ASF1B may be associated with chromosomal instability and aneuploidy. Besides, the 
expression pattern of lamin A, a nuclear periphery marker, was aberrant in ASF1A-inhibited 
cells where the abnormal nuclei were observed[125]. These findings collectively point out 
ASF1’s role in genome stability which should be an indispensable direction for ASF1 
research. 
5.5 ASF1 AND CANCER METASTASIS 
Cancer metastasis is the movement and colonization of tumor cells from their original sites to 
distant organs, becoming the major cause of cancer-related deaths[184]. The outcome of 
patients with or without metastasis differs substantially. Metastasis is considered a multi-step 
processes. During cancer development, tumor cells gain mutations and aberrant epigenetic 
features gradually and finally achieve the ability to invade and migrate to other tissues or 
organs. There are basically three types of metastasis genes based on expression 
signatures[185]: 1) metastasis initiation genes for the escape of cancer cells from the primary 
tumor such as genes favoring EMT. 2) metastasis progression genes for the survival of cancer 
cells in circulation system like EREG, MMP1 and LOX. 3) metastasis virulence genes for the 
final colonization in new organs including PTHRP, IL-11, IL-6 and TNFα)[186, 187]. 
Prevention and treatment in the earlier phase of carcinogenesis are important for the outcome. 
EMT is a very conserved biological process in evolution[188]. It also occurs in cancer 
development. EMT facilitates the transformation of cancer cells’ features from epithelial to 
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mesenchymal. Thus, cancer cells gain the ability for long-term migration and obtain some 
new features such as movement and stemness. Several major pathways are involved in 
EMT[188, 189]: Wnt/β-catenin, Notch, tumor growth factor (TGF), fibroblast growth factor 
(FGF) and epidermal growth factor receptor (EGFR) pathways. In GIC, the Wnt/β-catenin 
pathway plays an important role in malignant transformation. So in Paper I, we explored the 
interaction between ASF1A and Wnt/β-catenin in GIC. ASF1 proteins are likely to be highly 
involved in the metastasis process. In Paper III, we found that ASF1B expression was highly 
associated with ACC invasion and metastasis, which was a good biomarker for diagnosis 
since the survival of ACC patients was significantly longer in metastasis-free cases. Further 
studies are required to better elucidate the mechanisms of ASF1-mediated tumor metastasis. 
5.6 ASF1 AND EPIGENETIC THERAPY 
Cancer progression is a result of the interplay between genome and epigenome. The normal 
cells overcome genetic and epigenetic barriers and evolve to cancer cells[8]. In some even 
worse situations, cancer cells exposed to chemotherapeutic agents obtain new aggressive 
features and become resistant to further treatment which accounts for the major cause of 
cancer relapse[8]. A part of these newly-gained alterations during the rapid resistance period 
are epigenetic alterations. Different from the genetic alterations such as gene mutations which 
are difficult to change, all epigenetic modifications discovered by now are reversible[34]. 
Thus, targeting the epigenetic alterations and integrating epigenetic therapies into the 
traditional therapies should provide a new angle for cancer treatment. In addition, epigenomic 
targets are usually enzymes or small covalent modifications which are more ideal candidates 
for drug design than genomic targets[8]. 
Research on epigenetic drugs has made a lot of progress by now, including drugs targeting 
DNA methylation and histone modifications, some of which have been approved by the 
FDA. Examples are such as the DNA methylation inhibitors azacitidine, decitabine, and 
histone deacetylation inhibitors belinostat and panobinostat[8]. Notably, the bromodomain 
and extra terminal domain (BET) inhibitor JQ1 has been shown to be very efficient in 
specifically inducing growth inhibition and/or apoptosis in cancer cells[190]. JQ1 has also 
been proved to have the ability to inhibit histone H3K56 acetylation[191]. As mentioned 
above, ASF1A participates in and promotes H3K56 acetylation[122]. It will be interesting to 
investigate whether the inhibitory effect of H3K56 acetylation by JQ1 is mediated through 










6 SUMMARY, CONCLUSIONS AND FUTURE 
PERSPECTIVES 
 
In this thesis, the oncogenic role of the histone chaperones ASF1A and ASF1B was studied. 
Both ASF1A and ASF1B are overexpressed in the vast majority of human solid tumors. In 
GIC, ASF1A stimulates proliferation, stemness and migration/invasion of tumor cells, 
leading to poor patient outcomes. Mechanistically, ASF1A interacts with β-catenin and 
promotes the transcription of β-catenin target genes including c-MYC, cyclin D1, ZEB1 and 
LGR5. When ASF1A expression is inhibited, the DNA damage response is induced through 
which wt p53-bearing cancer cells undergo cellular senescence. Senescence similarly occurs 
in HCC, breast and PCa-derived cells with a wt p53 upon ASF1A depletion. For ACC, the 
ASF1B gene is amplified in two-thirds of tumors, which contributes to ASF1B 
overexpression and poor patient outcomes. ASF1B overexpression is highly correlated with 
the ACC diagnostic criteria of the Weiss scoring system. Our results further show that 
ASF1B up-regulates expression of the oncogene FoxM1, thereby promoting migration and 
invasion of ACC cells. Collectively, the results presented in this thesis reveal a key role of 
ASF1A and ASF1B in cancer cell proliferation, stemness and metastasis, suggesting that they 
may be novel epigenetic targets for cancer therapy. These findings, together with the potential 
values of ASF1A and ASF1B in cancer diagnostics and prognostication, should be of both 
biological and clinical importance. Further translational investigations are expected to pave 
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The only way to deal with an unfree world is to become so absolutely free 
that your very existence is an act of rebellion.  
                                                                          
                                                                                            —— Albert Camus <The  Rebel> 
  
 
